Head/Neck and Endocrine Flashcards

You may prefer our related Brainscape-certified flashcards:
1
Q

Fossa of Rosemillar cancer type and virus

A

nonkeartinizing and undifferentiated cancer, EBV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Field cancerization implications

A

H/N cancer may have second cancer in aerodigstrive tract

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Most important prognostic factor for H/N SCC

A

Stage at time of diagnosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Treatment of early stage H/N SCC

A

surgery or radiation (depending on performance status)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Role for accelerated fraction radiation

A

Only without chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Role for concomitant chemoradiation as front line

A

Locally advancement (stage III or IVA/B)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Chemo given with radiation for H/N SCC

A

Cisplatin or carboplatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Combination chemotherapy for metastatic or unresectable H/N SCC surgery unable to tolerate radiation

A

Cisplatin+5-FU+cetuximab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Second line therapy for metastatic H/N SCC

A

Nivo/Pembro or cetuxiumabn

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Treatment of salivary tumor

A

Resection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Orophayngeal cancer first line treatment

A

Chemoradiation with involvement of bilateral neck

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Treatment of persistent disease after completion of chemoreadiation

A

Surgery

Chemo (if not surgical candidate)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Familial syndromes for MTC

A

MEN2A and MEN2B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Mutations in differentiated thyroid cancer

A

BRAF V600E

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Indication for FNA in thyroid mass

A

Normal/high TSH or non-hyperfunctional nodule on radionucleotide scan

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Management of negative FNA

A

Rebiopsy in 3+ months

17
Q

Markers for MTC (2)

A

Calcitonin and CEA

18
Q

Total thyroidectomy indications (3)

A

> 4cm differentiated
MTC
Anaplastic (may need neoadjuvant therapy)

19
Q

Indications for RAI postthyroidectomy

A

Differentiated with extrathyroid extension

20
Q

TSH suppression role

A

Differentiated only, stage II+

21
Q

Monitoring after RAI

A

Tg, anti-Tg Ab

22
Q

Treatment of metastatic differentiated thyroid

A

Sorafanib or lenvatininib

23
Q

Treatment of metastatic MTC

A

Vandetanib or cabozantinib

24
Q

Treatment of anaplastic thyroid cancer

A

EBRT with doxorubicin radiosensitizing

25
Q

Systemic therapy for adrenocortical carcinoma

A

Platinum + etoposide + doxorubicin +mitotane

26
Q

Radiographic findings of adrenocortical carcinoma

A

> 10 Hounsfield units

Delayed washout, irregular borders

27
Q

Mutation associated with adrenocortical carcinoma

A

TP53

28
Q

Cell of origin for pheochromocytoma

A

chromaffin cell of adrenal medulla

29
Q

Genetic associations with pheochromocytoma (3)

A

MEN2A/2B
NF1
VHL

30
Q

Biochemical testing for pheochromocytoma

A

Fractionated plasma free metanephrines

24 hour urine fractionated metanephrines

31
Q

Preoperative care before pheo resection

A

alpha1 blockade (phenoxybenzamine)

32
Q

Scan for pheochromocytoma

A

131I-MIBG scan

33
Q

Metastatic pheochromocytoma chemo

A

cyclophosphamide, vincristine, dacarbazine

34
Q

Lymphoepithelial carcinoma virus

A

EBV